FDA Brief

Warning letters Devices

FDA warning letter to

Physitemp Instruments, LLC

High riskIssued Nov 12, 2025Posted Mar 31Center for Devices and Radiological Health

FDA says Physitemp sold clinical thermometers and temperature probes without FDA clearance and with unvalidated sterilization and welding.

What happened

FDA inspected Physitemp's Clifton, NJ plant from April 29 to June 18, 2025 and found the company was not following the quality system rule (CGMP, the manufacturing quality rules for devices), listing problems in process validation, finished-device testing, nonconforming product handling and complaints on a Form FDA 483 (the list of observations given at the end of an inspection). FDA also found the thermometers and probes on the market without premarket approval (PMA) or 510(k) clearance (FDA's two routes to legally sell a device). FDA reviewed the company's written reply and called it not adequate.

What FDA found

  1. The company did not validate its sterilization method or its laser welding process, so it could not show these steps reliably give sterile, correctly welded probes.

    21 CFR 820.75(a)
  2. Finished-device acceptance steps did not test whether the probes stay within the temperature tolerance the company advertises, including after welding.

    21 CFR 820.80(d)
  3. The nonconforming product procedure did not cover problems found when checking incoming materials, and staff did not record them or decide whether an investigation was needed.

    21 CFR 820.90(a)
  4. Rejected units often had no documented disposition, and reworked units were not retested or checked for harm from the rework.

    21 CFR 820.90(b)(1); 21 CFR 820.90(b)(2)
  5. The complaint system only handled returned products, had no instructions for deciding whether a complaint must be reported to FDA, and one emailed complaint about wrong TH-5 readings was never investigated.

    21 CFR 820.198(a); 21 CFR 820.198(c)
  6. The thermometers and probes were sold without an approved PMA or 510(k) clearance, and the firm did not notify FDA before putting them into commercial distribution.

    Section 501(f)(1)(B) and 502(o) of the Act, 21 U.S.C. 351(f)(1)(B), 352(o)

What FDA wants

FDA tells the company to respond in writing with a plan to fix each deficiency and supporting evidence, and to keep sending updates on the progress of its corrections and corrective actions. The letter as provided does not state a response deadline.

Who should pay attention

  • hospitals and surgical teams that buy clinical temperature probes and thermometers
  • distributors and group purchasing organizations that carry these device lines
  • contract manufacturers and brands that rely on a supplier's sterilization and process validations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk